Drug Profile
Influenza virus vaccine Begrivac - CSL
Alternative Names: Begrivac; Influenza-virus-vaccine-Begrivac-CSLLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Chiron
- Developer CSL
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis